The Europe Orthopedic Regenerative Surgical Products Market should witness market growth of 3.8% CAGR during the forecast period (2023-2030).
The market is probably going to expand due to the increasing prevalence of orthopedic illnesses around the region. Products used in orthopedic regenerative surgery are thought to prevent orthopedic issues like sprains, fractures, and strains, as well as lifelong disorders linked to continuous functional restrictions and disability. The traditional options for treating arthritis are surgical methods, such as joint replacement, and conservative management, such as mobility aids, physical therapy, and steroid injections. Conservative methods might be less efficient, but intrusive surgery has dangers to one's health and is painful.
Orthopedic surgeons are attempting to shift away from replacement or transplant and toward joint maintenance through the emerging discipline of regenerative medicine. By using orthobiologics, medical providers can give the body the cells, substances, and stimulation it requires to heal naturally without the need for surgery. The potential of regenerative medicine in the orthopedic field is a future when a joint replacement can be put off as long as feasible, potentially solving the problem of lengthy transplant waiting lists in other medical specialties.
According to projections, the EU-27's total population would grow slightly from 446.8 million at the beginning of 2019 to a peak of 449.3 million between 2026 and 2029. By the year 2050, 129.8 million older persons, those who are 65 years of age or older, will live in the EU-27, up from 90.5 million at the beginning of 2019. In the EU-27, it is anticipated that the population between the ages of 75 and 84 will rise by 56.1% during this time, while that between the ages of 65 and 74 is expected to rise by 16.6%. Additionally, it is among adults' most typical causes of physical impairment. Therefore, in the coming years, the growing proportion of aged people in the region will drive the expansion of the market.
The Germany market dominated the Europe Orthopedic Regenerative Surgical Products Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $361.2 million by 2030. The UK market is exhibiting a CAGR of 2.9% during (2023-2030). Additionally, The France market would experience a CAGR of 4.5% during (2023-2030).
Based on End-Use, the market is segmented into Hospitals, Ambulatory Surgical Centers and Others. Based on Application, the market is segmented into Joint Reconstruction, Cartilage & Tendon Repair, Trauma Repair, Orthopedic Pain Management and Others. Based on Product, the market is segmented into Viscosupplements, Allografts (Amniotic Products and Others), Synthetic and Cell-based. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include MiMedx Group, Inc., Vericel Corporation, Baxter International, Inc., Zimmer Biomet Holdings, Inc., Stryker Corporation, Smith & Nephew, Arthrex, Inc., BioTissue Holdings, Inc., VSY Biotechnology GmbH and Aptissen S.A.
The market is probably going to expand due to the increasing prevalence of orthopedic illnesses around the region. Products used in orthopedic regenerative surgery are thought to prevent orthopedic issues like sprains, fractures, and strains, as well as lifelong disorders linked to continuous functional restrictions and disability. The traditional options for treating arthritis are surgical methods, such as joint replacement, and conservative management, such as mobility aids, physical therapy, and steroid injections. Conservative methods might be less efficient, but intrusive surgery has dangers to one's health and is painful.
Orthopedic surgeons are attempting to shift away from replacement or transplant and toward joint maintenance through the emerging discipline of regenerative medicine. By using orthobiologics, medical providers can give the body the cells, substances, and stimulation it requires to heal naturally without the need for surgery. The potential of regenerative medicine in the orthopedic field is a future when a joint replacement can be put off as long as feasible, potentially solving the problem of lengthy transplant waiting lists in other medical specialties.
According to projections, the EU-27's total population would grow slightly from 446.8 million at the beginning of 2019 to a peak of 449.3 million between 2026 and 2029. By the year 2050, 129.8 million older persons, those who are 65 years of age or older, will live in the EU-27, up from 90.5 million at the beginning of 2019. In the EU-27, it is anticipated that the population between the ages of 75 and 84 will rise by 56.1% during this time, while that between the ages of 65 and 74 is expected to rise by 16.6%. Additionally, it is among adults' most typical causes of physical impairment. Therefore, in the coming years, the growing proportion of aged people in the region will drive the expansion of the market.
The Germany market dominated the Europe Orthopedic Regenerative Surgical Products Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $361.2 million by 2030. The UK market is exhibiting a CAGR of 2.9% during (2023-2030). Additionally, The France market would experience a CAGR of 4.5% during (2023-2030).
Based on End-Use, the market is segmented into Hospitals, Ambulatory Surgical Centers and Others. Based on Application, the market is segmented into Joint Reconstruction, Cartilage & Tendon Repair, Trauma Repair, Orthopedic Pain Management and Others. Based on Product, the market is segmented into Viscosupplements, Allografts (Amniotic Products and Others), Synthetic and Cell-based. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include MiMedx Group, Inc., Vericel Corporation, Baxter International, Inc., Zimmer Biomet Holdings, Inc., Stryker Corporation, Smith & Nephew, Arthrex, Inc., BioTissue Holdings, Inc., VSY Biotechnology GmbH and Aptissen S.A.
Scope of the Study
By End-use
- Hospitals
- Ambulatory Surgical Centers
- Others
By Application
- Joint Reconstruction
- Cartilage & Tendon Repair
- Trauma Repair
- Orthopedic Pain Management
- Others
By Product
- Viscosupplements
- Allografts
- Amniotic Products
- Others
- Synthetic
- Cell-based
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- MiMedx Group, Inc.
- Vericel Corporation
- Baxter International, Inc.
- Zimmer Biomet Holdings, Inc.
- Stryker Corporation
- Smith & Nephew
- Arthrex, Inc.
- BioTissue Holdings, Inc.
- VSY Biotechnology GmbH
- Aptissen S.A.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Europe Orthopedic Regenerative Surgical Products Market by End-use
Chapter 5. Europe Orthopedic Regenerative Surgical Products Market by Application
Chapter 6. Europe Orthopedic Regenerative Surgical Products Market by Product
Chapter 7. Europe Orthopedic Regenerative Surgical Products Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- MiMedx Group, Inc.
- Vericel Corporation
- Baxter International, Inc.
- Zimmer Biomet Holdings, Inc.
- Stryker Corporation
- Smith & Nephew
- Arthrex, Inc.
- BioTissue Holdings, Inc.
- VSY Biotechnology GmbH
- Aptissen S.A.
Methodology
LOADING...
